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In 1994, the Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 demonstrated a
two-thirds reduction of perinatal human immunodeficiency virus (HIV) type 1 transmission
with zidovudine chemoprophylaxis. However, zidovudine alone does not fully suppress HIV
replication, and chemoprophylaxis with zidovudine alone might select for zidovudine-resistant
viral variants, decreasing the efficacy of zidovudine prophylaxis and affecting future responses
to combined antiretroviral regimens. Sixty-two HIV-infected pregnant women consecutively
enrolled in the ongoing Swiss HIV and Pregnancy Study were prospectively evaluated for the
presence or development of zidovudine resistance by analysis of codon 215 of the reverse
transcriptase gene. Six women (9.6%) harbored a codon T215Y/F mutation, which is associated
with high-level resistance to zidovudine. Postnatal evaluation was completed in all children
of mothers harboring the mutation. None was HIV-infected. The observed prevalence of
codon 215 mutations of 9.6% raises important concerns regarding the future use of the PACTG
076 regimen.
Vertical transmission remains the major cause of human
immunodeficiency virus (HIV) infection in children, and the
reduction of transmission is a major concern worldwide. In
February 1994, the results of Pediatric AIDS Clinical Trials
Group (PACTG) Protocol 076 demonstrated that zidovudine
chemoprophylaxis during pregnancy, delivery, and to newborns
reduced perinatal HIV-1 transmission by two-thirds [1]. These
dramatic results have been confirmed in numerous epidemio-
logic studies [2] and in the final PACTG 076 study analysis [3],
and although more aggressive combination regimens are ac-
tually recommended for HIV-infected pregnant women [4], the
PACTG 076 regimen as recommended by the US Public Health
Service Task Force in 1994 [5] was the reference standard for
general clinical practice when this study was started. As zi-
dovudine monotherapy cannot achieve complete suppression
of viral replication, there is a concern that it might select for
zidovudine-resistant viral variants and thus decrease the efficacy
of the prophylaxis on transmission and affect future responses
to combined antiretroviral regimens.
A high rate of viral replication in conjunction with a high
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genetic variability due to low fidelity of viral reverse tran-
scriptase (RT) readily leads to the emergence of viral variants
resistant to antiretroviral drugs under selective pressure, espe-
cially with incompletely suppressive regimens. Several muta-
tions of the RT gene have been identified in patients treated
with zidovudine, the most common being the codon 215 mu-
tation [6]. Vertical transmission of a zidovudine-resistant virus
was first reported in 1994 [7], raising important concerns about
the efficacy of prophylactic zidovudine chemotherapy.
To evaluate the prevalence and the appearance of codon 215
mutation associated with zidovudine-resistance in HIV-infected
pregnant women and its consequences on vertical transmission,
we prospectively analyzed the presence or emergence of mu-
tations at codon 215 of the RT gene in 62 consecutive HIV-
infected pregnant women enrolled in the Swiss HIV and Preg-
nancy Study.
Patient Population and Methods
The Swiss HIV and Pregnancy Study enrolls HIV-infected preg-
nant women at any time during pregnancy until delivery or ter-
mination. A detailed history is obtained at enrollment; physical
examinations are performed and blood samples are collected for
immunologic, virologic, and hematologic evaluations at each tri-
mester, at delivery, and at 6 weeks and 6 months thereafter, ac-
cording to a standard protocol [8].
The infants are followed by the Swiss Neonatal HIV Study [9],
and virologic analyses are done during the first week of life and at
ages 2 and 6 months. Negative virologic test results are confirmed
serologically by seroreversion at age 18 months. Children are clas-
sified as infected if they have detectable HIV antibodies beyond
age 24 months or if they have positive virus detection test results
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by at least 2 methods (antigen after heat-mediated disruption of
immune complexes, polymerase chain reaction [PCR]) in >2 dif-
ferent samples. For classification as uninfected, the absence of HIV-
related symptoms and either no detectable HIV antibodies beyond
age 15 months or negative virus detection tests in >2 samples after
the age of 1 month by 2 different methods are required. All other
children are classified as indeterminate.
Sixty-two consecutively enrolled women were prospectively in-
cluded in a subprotocol started in March 1995 to evaluate zido-
vudine resistance by the detection of mutations at codon 215 of
the RT gene. The RT gene was sequenced in all patients with
mutation at codon 215.
Analysis of RT gene codon 215. Blood was collected without
anticoagulant, centrifuged twice for 5 min at 1500 g, aliquoted,
and stored at 2757C within 2 h. Total RNA in 50 mL of serum
was extracted using an automated system (model 540; Autogen
Instrument, Beverly, MA). RNA purification was based on the
single-step method of acid guanidinium thiocyanate–phenol–chlo-
roform extraction [10]. Total RNA was reverse transcribed and
amplified by selective PCR [11]. In brief, the first PCR step was
done with 0.25 mg of primers A (5′-AATTTTCCCATTAGTCCT-
ATT) and NE (5′-TATGTCATTGACAGTCCAGCT) with reac-
tion mixture that contained 50 mM KCl, 10 mM Tris-HCl (pH
8.3), 3 mM MgCl2, 10% glycerol, 200 mM of each dNTP, and 2.5
U of Amplitaq polymerase (Perkin-Elmer Cetus, Norwalk, CT).
One microliter of a 1:1- and 1:100-diluted PCR product was ream-
plified in a second selective PCR. To identify wild type mutant at
codon 215, primer pair B/3W was used, and primer B was paired
with 3M. The reactions were subjected to 35 cycles of 20 s at 957C,
30 s at 507C, and 30 s at 727C by DNA thermal cycler (Perkin-
Elmer Cetus). PCR products were separated through 2% Nu-Sieve
agarose. An alternative primer pair was used in first PCR for pa-
tients with negative results (NA 5′-CCTATTGAAACTGTAC-
CAGT and NNE 5′-ACTGTCCATTTATCAGGATG).
Direct sequencing of RT gene. Amplicons of the first PCR (5
mL) were reamplified with 0.25 mg of primers NNA 5′-AAGCCAG-
GAATGGATGGCCCA and E biotinylated 5′-CCATTTATCAG-
GATGGAGTTC in a reaction mixture containing 50 mM KCl,
10 mM Tris-HCl (pH 8.3), 3 mM MgCl2, 250 mM of each dNTP,
and 2.5 U of Amplitaq polymerase. The reactions were subjected
to 30 cycles of 20 s at 957C, 30 s at 507C, and 30 s at 727C. For
single-strand sequencing, 45 mL of nested PCR product was mixed
with 250 mg of streptavidin-coated magnetic beads (Dynabeads
M280; Dynal, Oslo) in 40 mL of 10 mM Tris-HCl (pH 7.5), 1 mM
EDTA, and 2 M NaCl and kept at room temperature for 20 min,
before the product was denatured with 16 mL of NaOH 0.1 M for
10 min and bead-bound single strand was recovered for sequencing.
The complementary strand was recovered from the supernatant
after purification by CentriSep column (Applied Biosystems, Foster
City, CA). Primer NNA was used to analyze the 30–130 codon
region and primer E for the 130–228 codon region. The nucleotide
sequence was determined by terminator cycle sequencing kit
(AmpliTaq FS dyedeoxy; Applied Biosystems) and automatic se-
quencer (model 373; Applied Biosystems). Sequence alignments
were done with PCGENE software (IntelliGenetics, Mountain
View, CA).
Results
Sixty-two consecutively enrolled HIV-infected women (64
newborns, 62 deliveries, 2 pairs of twins, 1 abortion, 1 woman
with 2 pregnancies) were included in this study. In total, 116
blood samples (mean, 1.8/woman; range, 1–5) were collected
for analysis of RT gene codon 215. Negative PCR results were
obtained in 19 samples (16%), most with !1000 HIV-1 RNA
copies/mL. A T215Y/F mutation associated with high-level zi-
dovudine resistance was found in 12 (12%) of 97 samples, cor-
responding to 6 (9.6%) of 62 women. However, the prevalence
of zidovudine-resistant variants may be underestimated, since
only the presence of mutations at codon 215 was analyzed.
Fifty-eight (95%) of 62 women were naive for antiretroviral
drugs at inclusion. Prophylactic zidovudine chemotherapy was
given to 51 women and their 52 neonates, including 1 pair of
twins. Seven women (11%) refused antiretroviral treatment. For
the remaining 4 pregnancies, no information regarding zido-
vudine chemoprophylaxis was available.
The 6 women harboring mutation at codon 215 tended to
be in a more advanced stage of HIV infection than patients
with 215 wild type virus with mean CD4 cells/mL of 333 5
for the former and for the latter (no statistical218 439 5 264
difference). Results of the codon 215 analysis and of antiretro-
viral therapy in these 6 women is shown in figure 1.
Mutation at codon 215 was detected in the first available
sample from patients 1, 2, 5, and 6. Patient 1 received zido-
vudine for 4 years before study entry. Patient 2 began zido-
vudine treatment 2 weeks after her last menstrual period be-
cause of immunologic deterioration, and codon 215 mutation
was detected after 24 weeks of treatment. In this patient, be-
cause of the detection of mutant virus, lamivudine was added
to zidovudine 1 month before delivery. Mutation at codon 215
was detected in the first available sample from patient 5 after
only 2 weeks of zidovudine treatment. She had received intra-
venous zidovudine during a previous delivery (11 months ear-
lier) and had not been treated with zidovudine before or be-
tween pregnancies. The retrospective analysis of a plasma
sample collected at the time of her first delivery revealed 215
wild type virus. Patient 6 was infected about the time of
conception, probably with a mutant virus strain, as the 215
mutation was detected on the first available sample before in-
itiation of zidovudine prophylaxis, within 1 year after serocon-
version. Her neonate was given oral didanosine in addition to
postnatal zidovudine treatment (weeks 2–6 after birth).
Development of mutation at codon 215 during zidovudine
therapy was observed in at least 1, possibly 2 formerly zido-
vudine-naive patients: patient 3 after 17 weeks (11 weeks in
combination with lamivudine) and likely in patient 4 after 22
weeks of zidovudine monotherapy. This patient showed a mixed
population of wild type and mutant virus in the first available
sample.
HIV infection status was determined for 46 children (72%);
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Figure 1. Antiretroviral prophylaxis and analysis of resistance mutations of reverse transcriptase (RT) gene in 6 pregnant HIV-infected women.
iv, intravenous; ddI, didanosine; PACTG, Pediatric AIDS Clinical Trials Group; 3TC, lamivudine; ZDV, zidovudine.
Table 1. Characteristics of the 3 HIV-transmitting women at delivery.
Child
HIV RNA
(copies/mL)
CD4
(cells/L)
CDC
stage
Mode of
delivery
Age
(weeks)
Time from membrane
rupture to birth
Zidovudine
(weeks)a Remarks
A 68,517 16 B3 SC 28 160 h 1 week
B NA NA A1 V 42 15 min 28 weeks Methadone during pregnancy
C NA 443 A2 SC 34 18 h 6 weeks HIV-1 and -2 coinfection in mother
NOTE. NA, not available; SC, secondary cesarean; V, vaginal.
a Duration of zidovudine therapy before delivery.
the remaining 18 children could not be classified because of
young age or because the parents refused testing. Forty-three
children are known to be HIV-negative and 3 children are in-
fected, resulting in a transmission rate of 6.5%. Characteristics
of the mothers who transmitted the infection are shown in table
1. None of the 7 children born to mothers with a mutation at
codon 215 was infected (95% confidence interval, 0%–41%).
Discussion
Zidovudine was the most widely used antiretroviral drug be-
tween 1987 and 1995, and HIV variants with decreased sus-
ceptibility to zidovudine were first reported in 1989 [12]. Se-
quencing of the HIV RT gene revealed a number of mutations
that influence viral sensitivity to zidovudine and thus can be
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used as genotypic markers for the presence of zidovudine re-
sistance. Horizontal transmission of zidovudine-resistant virus
was first reported in 1993 [13].
Our data demonstrate that virus bearing T215Y/F mutant
codon associated with high-level zidovudine resistance is fre-
quently detected in HIV-infected pregnant women, since it was
found in 6 of 62 consecutive pregnant women (prevalence,
9.6%). Our data suggest that mutant variants may develop un-
der the selective pressure of zidovudine prophylaxis during
pregnancy.
The mechanisms for the reduction of vertical transmission
with zidovudine chemoprophylaxis according to PACTG 076
are still not fully understood. Results of a large study dem-
onstrate that the effect on maternal HIV-1 RNA level cannot
fully account for the observed efficacy of zidovudine in reducing
transmission and that preexposure prophylaxis of the fetus/
infant could be an important protective component [3]. In a
previous evaluation of genotypic resistance in women of the
PACTG 076 study [14], none of the women showed high-level
zidovudine resistance at study entry or delivery.
None of the 7 children born to mothers harboring mutation
at codon 215 was vertically infected. However, given an actual
transmission rate of !10% with chemoprophylaxis alone and
even less when combined with a primary cesarean section [9],
much larger numbers of mother-child pairs will be needed to
estimate the effect of mutations associated with resistance on
the efficacy of zidovudine prophylaxis. It also remains to be
seen whether the emergence of resistance mutations due to zi-
dovudine chemotherapy during pregnancy could adversely in-
fluence the subsequent evolution of HIV infection in women
and in infected children.
In conclusion, although emergence of mutations associated
with zidovudine resistance are of concern, as they are present
in 9.6% of our subjects, they were not associated with infection
in newborns. This might support zidovudine prophylaxis in
countries where access to antiretroviral drugs is limited. Current
recommendations for antiretroviral treatment in pregnant
women [4] include protease inhibitor–containing regimens. Re-
cent data indicate that these regimens may be associated with
potential toxicity in the newborn and, thus, optimal drug reg-
imens remain to be defined [15].
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